US patients staying on Wegovy obesity drug for ‘around six months’, Novo Nordisk says

LONDON (Reuters) – U.S. patients are staying on Novo Nordisk (NYSE:)’s Wegovy weight-loss medication for “around six months”, an executive said on Wednesday, adding that the company is confident that over time as shortages ease that will increase to 12 months.

Doug Langa, Novo’s head of North America operations, was speaking on a call with analysts after the company trimmed its full-year profit outlook after reporting weaker-than-expected quarterly sales of Wegovy.